New York Assembly Bill A02725

New York 2025-2026 Regular Session

• Introduced: 1/22/25
• Refer: 1/22/25
• Report Pass: 4/30/25
• Engrossed: 5/5/25
• Refer: 5/5/25
• Engrossed: 6/6/25

Caption

Requires employers to include an opioid antagonist where first aid kits are required by federal law.

Impact

If passed, this legislation will require a review and possible adjustment of the first aid supplies kept by many businesses and organizations throughout the state. Employers may need to procure opioid antagonists and ensure that employees are trained in their use. The addition of this requirement would not only improve emergency preparedness in workplaces but may also foster a culture of safety and awareness concerning the dangers of opioid abuse.

Summary

Bill A02725 aims to enhance workplace safety in New York by mandating that employers include an opioid antagonist, such as naloxone, in their first aid supplies. This requirement will apply to all employers who are already federally mandated to maintain first aid kits for their employees. By ensuring the availability of opioid antagonists in the workplace, the bill seeks to provide critical life-saving interventions in the event of opioid overdoses, thereby contributing to public health efforts related to the opioid crisis.

Contention

Notable points of discussion surrounding Bill A02725 include concerns regarding the potential financial burden it may impose on small businesses. Some stakeholders argue that the cost of purchasing opioid antagonists and conducting training sessions could be significant, particularly for smaller employers with limited resources. However, advocates for the bill emphasize the lifesaving importance of having these medications readily available and suggest that the potential healthcare cost savings from preventing overdoses should outweigh any additional expenses.

Additional_notes

The bill represents a proactive step in addressing the ongoing epidemic of opioid overdoses, which has become a pressing public health issue. By equipping workplaces with opioid antagonists, the legislation aligns with broader state and national efforts to combat the opioid crisis.